The clinical success of the recent DAWN trial has been recognized as a revolutionary milestone in stroke and represents a significant achievement in advancing stroke care and expanding the treatment window from 6 to 24 hours and building on the foundation of the trials of 2014 through 2017.
In this special Stryker symposium, which was held on Monday, June 11th during the
LINNC Paris 2018
and chaired by Prof. Raul G. Nogueira (Atlanta, Georgia, USA), data from DAWN, the TREVO Registry, AUORA and other landmark trials supported by Stryker was presented by Professor Christophe Cognard (Toulouse, France), along with crucial treatment techniques supporting good patient outcomes which was presented by Professor Anastasios Mpotsaris (Aachen, Germany).
As iterated by Pr. Cognard, we must remain, , conscious of the importance of the element of time for all stroke patients. Is there too much time spent on imaging? And how much imaging is really needed…and why? Could less imaging be an element in which, decreased time spent on imaging and streamlining the transfer and treatment process, more patients can be treated and with less disability?
Pr.. Mpotsaris challenged us to “further raise the bar for first-pass efficacy through the continued optimization of mechanical thrombectomy itself” and examined which method works best when the aim is to have 100% mRS 0 at 90d.
His answer? The use of balloon guide catheters to reduce angio-duration and increase reperfusion rates and maximizing first pass complete reperfusion with “SAVE”, a technique he describes with data released during the symposium.
The symposium also looked at real world practice through the ongoing Trevo Registry, the largest all-comers stent-retriever thrombectomy registry for LVO patients to date with more than 2000 patients enrolled, which offers a solid and broad database to further explore the various treatment algorithms and trends.
Future treatments and innovative technologies are being developed. . Through the ongoing sharing of experience, the development and evolution of innovative devices and the continuation of widespread trials and registries – the goal is to continue to provide patients suffering from stroke the possibility of a future with less disabilities and better quality of life.